HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by HERRERA, S. Articles by ARÉVALO-HERRERA, M. Search for Related Content PubMed PubMed Citation Articles by HERRERA, S. Articles by ARÉVALO-HERRERA, M.

ANTIBODY RESPONSE TO PLASMODIUM VIVAX ANTIGENS IN FY-NEGATIVE INDIVIDUALS FROM THE COLOMBIAN PACIFIC COAST

The Duffy antigen (Fy) is necessary for Plasmodium vivax invasion of human erythrocytes. Some populations have a highly prevalent Fy-negative phenotype; such persons are naturally protected from P. vivax blood infection but are expected to completely support the P. vivax pre-erythrocytic cycle, representing a valuable model for studying the immune response during these parasitic stages. We typed 214 individuals, mostly Afro-Colombians, from a P. vivax-endemic area for Fy expression and determined the antibody response to P. vivax pre-erythrocytic (sporozoites and CS) and blood-stage antigens (blood forms, P. vivax merozoite surface protein 1, and P. vivax Duffy binding protein [PvDBP]). Antibody titers to P. vivax circumsporozoite protein, P11, and N-terminal peptides and the number of responders were similar in Fy-negative and Fy-positive individuals. The number of responders to sporozoites, blood forms, and PvDBP were different between these groups. Thus, Fy-negative individuals from malaria-endemic areas can be used to study the immune response to the P. vivax liver phase without interference of the erythrocytic cycle.

Received April 12, 2005. Accepted for publication June 17, 2005.

Acknowledgments: We thank Anilza Bonelo and Ana Milena Lenis for scientific and technical support in the assessment of the humoral response, Rosalie Dominik and Hugo Hurtado for statistical advice, and Lina González for collection of field samples.

Financial support: This work was supported by the National Institute of Allergy and Infectious Diseases (Bethesda, MD) through a Tropical Medicine Research Center grant (no. 5 P50 AI049486-01). Chetan E. Chitnis is supported by an International Senior Research Fellowship from The Wellcome Trust, United Kingdom and an International Research Scholarship from the Howard Hughes Medical Institute.

^* Address correspondence to Sócrates Herrera, Malaria Vaccine and Drug Development Center, Carrera 35 # 4A-53, AA 26020, Cali, Colombia. E-mail: sherrera{at}inmuno.org

Authors’ addresses: Sócrates Herrera, Andrés Gómez, Omaira Vera, Juana Vergara, Augusto Valderrama-Aguirre, Fabián Méndez, and Myriam Arévalo-Herrera, Instituto de Inmunología, Edificio de Microbiología, Tercer Piso, Facultad de Salud, Universidad del Valle, Sede San Fernando, AA 25574, Cali, Colombia, Telephone: 57-2-558-1931, Fax: 57-2-557-0449 and Malaria Vaccine and Drug Development Center, Carrera 35 # 4A-53, AA 26020, Cali, Colombia, Telephone: 57-2-558-3937, Fax: 57-2-556-0141, E-mail: sherrera{at}inmuno.org. Amanda Maestre, Grupo de Malaria, Universidad de Antioquia, Calle 62 # 52-59, Medellín, Colombia. Ruobing Wang, The Institute for Genomic Research, 9712 Medical Center Drive, Rockville, MD 20850, Telephone: 301-315-2524. Chetan E. Chitnis and Syed S. Yazdani, International Center for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg 110 067, New Delhi, India, Telephone: 91-11-2619-5007.

Reprint requests: Sócrates Herrera, Malaria Vaccine and Drug Development Center, Carrera 35 No 4A-53, Cali, Colombia.

This article has been cited by other articles:

				W L Irving Acute hepatitis C virus infection: a neglected disease? Gut, August 1, 2006; 55(8): 1075 - 1077. [Full Text] [PDF]